Dimethyl fumarate induced lymphopenia in multiple sclerosis: A review of the literature
- 1 March 2021
- journal article
- review article
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 219, 107710
Abstract
No abstract availableKeywords
Funding Information
- Bristol-Myers Squibb
This publication has 131 references indexed in Scilit:
- Bacterial lipodipeptide, Lipid 654, is a microbiome‐associated biomarker for multiple sclerosisClinical & Translational Immunology, 2013
- Isolation of Clostridium perfringens Type B in an Individual at First Clinical Presentation of Multiple Sclerosis Provides Clues for Environmental Triggers of the DiseasePLOS ONE, 2013
- Anti-Inflammatory Effects of Nicotinic Acid in Human Monocytes Are Mediated by GPR109A Dependent MechanismsArteriosclerosis, Thrombosis, and Vascular Biology, 2012
- Anaerobic Respiration of Escherichia coli in the Mouse IntestineInfection and Immunity, 2011
- Nicotinic acid– and monomethyl fumarate–induced flushing involves GPR109A expressed by keratinocytes and COX-2–dependent prostanoid formation in miceJournal of Clinical Investigation, 2010
- The Nrf2-Antioxidant Response Element Signaling Pathway and Its Activation by Oxidative StressJournal of Biological Chemistry, 2009
- The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonistBiochemical and Biophysical Research Communications, 2008
- Respiration of Escherichia coli in the Mouse IntestineInfection and Immunity, 2007
- Antipsoriatic effect of fumaric acid derivativesJournal of the American Academy of Dermatology, 1994
- Systemic therapy with fumaric acid derivates: New possibilities in the treatment of psoriasisJournal of the American Academy of Dermatology, 1989